Related Experiment Video
Updated: Apr 17, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C
Juan Pablo Trivella1, Julio Gutierrez, Paul Martin
1University of Miami/Jackson Memorial Hospital, Department of Gastroenterology and Hepatology , 1500 NW 12 Ave, Jackson Medical Tower E-1101, Miami, Fl 33136 , USA.
Introduction:
Treatment of hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) has revolutionized the care of infected patients. Among these novel compounds are non-nucleoside analogs, which bind viral RNA-dependent RNA polymerase resulting in a conformational change inhibiting RNA synthesis.
Areas Covered:
Efficacy and tolerability of treatment regimens containing the non-nucleoside analog polymerase inhibitor dasabuvir (ABT-333).
Expert Opinion:
Dasabuvir-containing regimens achieve high rates of sustained virologic response in HCV genotype 1a and 1b-infected patients when combined with other DAAs, namely paritaprevir (ABT-450), ritonavir and ombitasvir (ABT-267). In the populations studied, dasabuvir seems to be well tolerated and safe. The major limitations of this novel drug are its genotype-restricted activity, the necessity to include ribavirin for HCV genotype 1a and the emergence of resistance if not combined with other DDAs.
Related Concept Videos
Retrovirus Life Cycles
Hepatitis
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Subviral Agents
Retroviruses

